MEK inhibition in combination with PI3K/AKT/MTOR is a promising therapeutic in basal bladder cancer.

被引：0
|
作者：
Apfel, Athena M. [1 ]
Merrill, Nathan M. [1 ]
Vandecan, Nathalie M. [1 ]
Bao, Liwei [1 ]
Cheng, Xu [1 ]
Lopez-Barcons, Lluis A. [1 ]
Day, Kathleen C. [1 ]
Palmbos, Phillip L. [1 ]
Day, Mark L. [1 ]
Udager, Aaron M. [1 ]
Soellner, Matthew B. [1 ]
Merajver, Sofia D. [1 ]
机构：
[1] Univ Michigan, Ann Arbor, MI 48109 USA
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1194
引用
收藏
页数：1
相关论文
共 50 条
  • [41] PI3K/Akt/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy
    Manfredi, Gloria Irene
    Dicitore, Alessandra
    Gaudenzi, Germano
    Caraglia, Michele
    Persani, Luca
    Vitale, Giovanni
    ENDOCRINE, 2015, 48 (02) : 363 - 370
  • [42] Potential Therapeutic Roles for Inhibition of the PI3K/Akt/mTOR Pathway in the Pathophysiology of Diabetic Retinopathy
    Jacot, Jorge L.
    Sherris, David
    JOURNAL OF OPHTHALMOLOGY, 2011, 2011
  • [43] Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway
    Dongshao Chen
    Xiaoting Lin
    Cheng Zhang
    Zhentao Liu
    Zuhua Chen
    Zhongwu Li
    Jingyuan Wang
    Beifang Li
    Yanting Hu
    Bin Dong
    Lin Shen
    Jiafu Ji
    Jing Gao
    Xiaotian Zhang
    Cell Death & Disease, 9
  • [44] Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway
    Chen, Dongshao
    Lin, Xiaoting
    Zhang, Cheng
    Liu, Zhentao
    Chen, Zuhua
    Li, Zhongwu
    Wang, Jingyuan
    Li, Beifang
    Hu, Yanting
    Dong, Bin
    Shen, Lin
    Ji, Jiafu
    Gao, Jing
    Zhang, Xiaotian
    CELL DEATH & DISEASE, 2018, 9
  • [45] Targeted Therapy for Advanced Prostate Cancer: Inhibition of the PI3K/Akt/mTOR Pathway
    Morgan, Todd M.
    Koreckij, Theodore D.
    Corey, Eva
    CURRENT CANCER DRUG TARGETS, 2009, 9 (02) : 237 - 249
  • [46] Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer
    Cirone, Pasquale
    Andresen, Catharine J.
    Eswaraka, Jeetendra R.
    Lappin, Patrick B.
    Bagi, Cedo M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (03) : 525 - 538
  • [47] Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer
    Pasquale Cirone
    Catharine J. Andresen
    Jeetendra R. Eswaraka
    Patrick B. Lappin
    Cedo M. Bagi
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 525 - 538
  • [48] Selective Eradication of Colon Cancer Cells Harboring PI3K and/or MAPK Pathway Mutations in 3D Culture by Combined PI3K/AKT/mTOR Pathway and MEK Inhibition
    Atanasova, Velina S.
    Riedl, Angelika
    Strobl, Marcus
    Flandorfer, Julia
    Unterleuthner, Daniela
    Weindorfer, Claudia
    Neuhold, Patrick
    Stang, Simone
    Hengstschlaeger, Markus
    Bergmann, Michael
    Dolznig, Helmut
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (02)
  • [49] Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma
    Guenther, Monika Katharina
    Graab, Ulrike
    Fulda, Simone
    CANCER LETTERS, 2013, 337 (02) : 200 - 209
  • [50] Regulation of ferroptosis by PI3K/Akt signaling pathway: a promising therapeutic axis in cancer
    Su, Hua
    Peng, Chao
    Liu, Yang
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2024, 12
12345